<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526617</url>
  </required_header>
  <id_info>
    <org_study_id>M06-862</org_study_id>
    <nct_id>NCT00526617</nct_id>
  </id_info>
  <brief_title>A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients</brief_title>
  <official_title>A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given&#xD;
      together with Temozolomide (chemotherapy) in treating patients with solid tumors, including&#xD;
      metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian&#xD;
      tube cancer, and hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, multicenter, dose-escalation study evaluating the safety and tolerability of the&#xD;
      PARP inhibitor ABT-888 in combination with Temozolomide (TMZ) in subjects with&#xD;
      non-hematologic malignancies (NHM), including metastatic melanoma (MM), BRCA deficient&#xD;
      breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma&#xD;
      (HCC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Non-hematologic Malignancies</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Oral capsules</description>
    <arm_group_label>Open Label</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Dose escalation and expanded safety cohorts&#xD;
&#xD;
          -  Evaluable disease, histologically confirmed malignancy (metastatic or unresectable)&#xD;
             and standard curative measures or other therapy that may provide clinical benefit do&#xD;
             not exist or are no longer effective&#xD;
&#xD;
          -  ECOG Performance Score less than or equal to 2&#xD;
&#xD;
          -  Adequate hematologic, renal and hepatic function&#xD;
&#xD;
          -  Normal sodium, calcium and magnesium levels&#xD;
&#xD;
          -  Voluntarily signed informed consent&#xD;
&#xD;
        Expanded Safety Cohorts Only&#xD;
&#xD;
          -  Population:&#xD;
&#xD;
          -  Metastatic melanoma (MM)&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC) Child Pugh Category A and B classification only&#xD;
&#xD;
          -  BRCA deficient tumor status*: advanced breast cancer (with soft tissue disease), or&#xD;
             advanced ovarian cancer, or advanced primary peritoneal cancer, or advanced fallopian&#xD;
             tube cancer*&#xD;
&#xD;
             *Patients must have histologically or cytologically confirmed solid tumors with a&#xD;
             positive genetic test result documenting BRCA 1 or BRCA 2 mutation status, to be&#xD;
             considered eligible.&#xD;
&#xD;
          -  Serial tumor biopsies: Required for all subjects enrolled in one of the Expanded Low&#xD;
             Dose Safety Cohorts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Dose Escalation and Expanded Safety Cohorts&#xD;
&#xD;
          -  Known central nervous system (CNS) metastases or CNS primary cancer.&#xD;
&#xD;
          -  Previous or current malignancies at other sites, except: adequately treated in situ&#xD;
             carcinoma of cervix uteri; basal/squamous cell carcinoma of skin; previous malignancy&#xD;
             considered cured.&#xD;
&#xD;
          -  Previous history or current seizure disorder.&#xD;
&#xD;
          -  Clinically significant and uncontrolled major medical condition(s) or any medical&#xD;
             condition that places the subject at an unacceptably high risk for toxicities.&#xD;
&#xD;
          -  Transplant recipients and patients receiving combination anti-retroviral therapy for&#xD;
             HIV due to the use of immunosuppressant therapies.&#xD;
&#xD;
          -  Lactating or pregnant female.&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy&#xD;
             will not be allowed within either 4 weeks, or 5 half lives of a targeted therapy prior&#xD;
             to study drug administration (Study Day 1).&#xD;
&#xD;
          -  Prior therapy with regimens containing dacarbazine (DTIC) or TMZ is not permitted.&#xD;
&#xD;
          -  Anti-cancer therapy is not permitted during the treatment portion of the study.&#xD;
&#xD;
          -  Hormone therapy, bisphosphonates or LHRH-agonists for prostate cancer are permitted&#xD;
             prior to and during the study.&#xD;
&#xD;
          -  Significant adverse event or toxicity due to previous anti-cancer treatment that has&#xD;
             not recovered to within one grade level (not to exceed Grade 2) of baseline.&#xD;
&#xD;
        Expanded Safety Cohorts Only:&#xD;
&#xD;
          -  MM Only: Prior treatment with DNA damaging agents or cytotoxic chemotherapy including&#xD;
             carboplatin, cisplatin, fotemustine, paclitaxel, vincristine, TMZ and DTIC.&#xD;
&#xD;
          -  Prior therapy with biologic agents (including IL-2, interferon, bevacizumab, vaccines&#xD;
             and immunostimulants) and signal transduction inhibitors (including sorafenib,&#xD;
             erlotinib, sutent and elesclomol) are allowed.&#xD;
&#xD;
        Lower Dose Expanded Safety Cohorts Only&#xD;
&#xD;
          -  Anti-coagulant restrictions for subjects that have tumor biopsies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhardwaj Desai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018 Jan;57(1):51-58. doi: 10.1007/s40262-017-0547-z.</citation>
    <PMID>28497258</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>BRCA deficient</keyword>
  <keyword>BRCA mutation</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Temodar</keyword>
  <keyword>TMZ</keyword>
  <keyword>ABT-888</keyword>
  <keyword>PARP inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

